We observed a rather low expression of FABP3 in endothelium and an increased level of circulating FABP3 in LPS-treated mice; however, it remains to be seen whether the endothelium is a significant source of FABP3 in LPS-treated mice and in PAD patients. This evidence concerns the gene FABP3 and peripheral arterial disease.